EA202191926A3 - Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии - Google Patents

Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии

Info

Publication number
EA202191926A3
EA202191926A3 EA202191926A EA202191926A EA202191926A3 EA 202191926 A3 EA202191926 A3 EA 202191926A3 EA 202191926 A EA202191926 A EA 202191926A EA 202191926 A EA202191926 A EA 202191926A EA 202191926 A3 EA202191926 A3 EA 202191926A3
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
disease virus
newcastle disease
neoplasia
treatment
Prior art date
Application number
EA202191926A
Other languages
English (en)
Other versions
EA202191926A2 (ru
Inventor
Синг Чэнг
Дэниелл Кэрролл
Мэттью Маккурт
Марк Галински
Хон Цзинь
Original Assignee
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед filed Critical Медиммун Лимитед
Publication of EA202191926A2 publication Critical patent/EA202191926A2/ru
Publication of EA202191926A3 publication Critical patent/EA202191926A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении раскрыты способы индуцирования регрессии опухолей у субъектов-людей, при этом в способах используется модифицированный мезогенный штамм вируса ньюкаслской болезни (NDV) с модифицированным сайтом расщепления F-белка, который является непатогенным для домашней птицы (лентогенный), но проявляет онколитические свойства. Раскрытые способы обеспечивают безопасное, эффективное и надежное средство для индуцирования регрессии опухоли у индивида, нуждающегося в этом. Эти способы преодолевают недостатки применения патогенных штаммов вирусов для терапии человека.
EA202191926A 2013-09-03 2014-09-02 Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии EA202191926A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03

Publications (2)

Publication Number Publication Date
EA202191926A2 EA202191926A2 (ru) 2021-10-29
EA202191926A3 true EA202191926A3 (ru) 2022-01-31

Family

ID=51492938

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690425A EA039404B1 (ru) 2013-09-03 2014-09-02 Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием
EA202191926A EA202191926A3 (ru) 2013-09-03 2014-09-02 Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690425A EA039404B1 (ru) 2013-09-03 2014-09-02 Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием

Country Status (24)

Country Link
US (2) US10519426B2 (ru)
EP (3) EP3041490B1 (ru)
JP (2) JP6557234B2 (ru)
KR (2) KR102310692B1 (ru)
CN (2) CN111944767A (ru)
AU (2) AU2014317215C1 (ru)
CA (1) CA2922071C (ru)
CY (1) CY1121993T1 (ru)
DK (2) DK3041490T3 (ru)
EA (2) EA039404B1 (ru)
ES (2) ES2708755T3 (ru)
HK (2) HK1225643B (ru)
HR (2) HRP20220653T1 (ru)
HU (1) HUE042382T2 (ru)
LT (2) LT3041490T (ru)
ME (1) ME03345B (ru)
MX (2) MX367768B (ru)
PL (2) PL3508209T3 (ru)
PT (2) PT3041490T (ru)
RS (2) RS63291B1 (ru)
SI (2) SI3041490T1 (ru)
TR (1) TR201902073T4 (ru)
TW (1) TWI653334B (ru)
WO (1) WO2015032755A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
GEP20196976B (en) 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
CA2922071C (en) * 2013-09-03 2022-05-03 Medimmune Limited Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
US10563178B2 (en) * 2015-04-28 2020-02-18 University Of Georgia Research Foundation, Inc. PIV5-based amplifying virus-like particles
EP3246410A1 (en) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
US20200297787A1 (en) * 2018-07-13 2020-09-24 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
ATE451835T1 (de) * 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (en) * 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
GEP20196976B (en) * 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
CA2922071C (en) * 2013-09-03 2022-05-03 Medimmune Limited Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Also Published As

Publication number Publication date
AU2014317215A8 (en) 2016-04-21
PT3041490T (pt) 2019-02-06
SI3041490T1 (sl) 2019-03-29
DK3508209T3 (da) 2022-05-30
CA2922071A1 (en) 2015-03-12
US20160208222A1 (en) 2016-07-21
CA2922071C (en) 2022-05-03
LT3041490T (lt) 2019-02-25
AU2019204419A1 (en) 2019-07-11
KR102310692B1 (ko) 2021-10-12
TWI653334B (zh) 2019-03-11
KR20210048605A (ko) 2021-05-03
EP3041490A1 (en) 2016-07-13
ES2708755T3 (es) 2019-04-11
KR102285894B1 (ko) 2021-08-04
PT3508209T (pt) 2022-05-27
WO2015032755A1 (en) 2015-03-12
PL3041490T3 (pl) 2019-05-31
CY1121993T1 (el) 2020-10-14
SI3508209T1 (sl) 2023-01-31
MX2016002771A (es) 2016-09-06
RS58332B1 (sr) 2019-03-29
CN106163532A (zh) 2016-11-23
JP2016533749A (ja) 2016-11-04
DK3041490T3 (en) 2019-03-04
US10519426B2 (en) 2019-12-31
HRP20190250T1 (hr) 2019-05-31
AU2014317215C1 (en) 2019-09-12
EP3508209B1 (en) 2022-03-09
RS63291B1 (sr) 2022-06-30
US11471499B2 (en) 2022-10-18
TR201902073T4 (tr) 2019-03-21
EA039404B1 (ru) 2022-01-24
HRP20220653T1 (hr) 2022-06-24
US20200181581A1 (en) 2020-06-11
PL3508209T3 (pl) 2022-06-13
MX2019010364A (es) 2019-10-07
EA202191926A2 (ru) 2021-10-29
TW201606079A (zh) 2016-02-16
EP4101457A1 (en) 2022-12-14
HUE042382T2 (hu) 2019-06-28
HK1231393A1 (zh) 2017-12-22
AU2014317215B2 (en) 2019-03-28
JP6862500B2 (ja) 2021-04-21
ES2914577T3 (es) 2022-06-14
AU2019204419B2 (en) 2021-09-02
JP6557234B2 (ja) 2019-08-07
LT3508209T (lt) 2022-06-10
JP2019193662A (ja) 2019-11-07
EP3508209A1 (en) 2019-07-10
ME03345B (me) 2019-10-20
EA201690425A1 (ru) 2016-08-31
CN111944767A (zh) 2020-11-17
KR20160047570A (ko) 2016-05-02
EP3041490B1 (en) 2018-11-14
AU2014317215A1 (en) 2016-04-14
MX367768B (es) 2019-09-05
HK1225643B (zh) 2017-09-15
CN106163532B (zh) 2019-12-31

Similar Documents

Publication Publication Date Title
EA202191926A3 (ru) Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии
CY1123404T1 (el) Αντι-girt αντισωματα
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
BR112014019049A2 (pt) adenovirus imunogênico
CU20110206A7 (es) Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
EA201691443A1 (ru) Накожное восстановление иммунобаланса
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
CL2014003113A1 (es) Composición que comprende bacterias inactivadas de alliivibrio wodanis; método de producción; uso para fabricar medicamento para tratar y/o prevenir wodanosis; y vacuna para peces.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112016006210A2 (pt) terapia e vacina contra gripe
CY1122834T1 (el) Παραγωγα χλωρινης χρησιμα στη φωτοδυναμικη θεραπεια και τη διαγνωση
PH12016500960A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
CO6700818A2 (es) Vectores de parapoxvirus
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
NZ754298A (en) Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
PH12014501688A1 (en) Influenza c virus and vaccine